Tirzepatide in An Giang: How Clinical Trials Evaluate Glycemic Control and Body Weight Separately
Featured Answer: Why Do Trials Measure Blood Sugar and Body Weight Separately?
Clinical trials evaluate glycemic control and body weight separately because they represent different outcomes. Glycemic control describes how well blood glucose is regulated, commonly measured by glycated hemoglobin (HbA1c), fasting glucose, and the proportion of participants reaching prespecified glycemic targets. Body-weight outcomes measure changes in kilograms or percentage of baseline weight and may include the proportion of participants achieving thresholds such as 5%, 10%, or 15% weight reduction.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated improvements in both outcomes. However, a reduction in HbA1c does not automatically tell researchers how much weight a participant lost, and weight loss alone does not establish how well glucose was controlled.
In the 40-week SURPASS-1 trial involving adults with type 2 diabetes, HbA1c decreased by approximately 1.87–2.07 percentage points across the studied tirzepatide groups, while mean body-weight reductions ranged from 7.0 to 9.5 kg. The trial assessed both outcomes, but they answered different research questions.
Bottom line: Glycemic control and body weight are related but distinct endpoints. Evaluating them separately helps researchers understand the treatment’s effects, compare results fairly, and avoid treating a single favorable number as a complete measure of clinical benefit.
Key Takeaways
- HbA1c measures longer-term glycemia. It reflects average blood glucose over approximately two to three months, while fasting glucose and continuous glucose monitoring provide complementary information.
- Body weight is a separate endpoint. Trials may report kilograms lost, percentage change from baseline, and the proportion of participants reaching predefined weight-loss thresholds.
- One outcome cannot substitute for the other. A lower HbA1c does not quantify weight loss, and a lower body weight does not prove that glycemic targets were achieved safely.
- SURPASS trials primarily studied type 2 diabetes. Many used HbA1c change as the primary endpoint and weight change as a key secondary endpoint.
- SURMOUNT-1 studied a different population. It enrolled adults with obesity or overweight and a weight-related complication, excluding those with diabetes, and used weight outcomes as coprimary endpoints.
- Baseline values affect interpretation. Starting HbA1c, body weight, diabetes duration, background medications, and trial eligibility influence how results should be understood.
- Percentage change and absolute change are different. A 10% reduction means different numbers of kilograms for participants with different starting weights.
- Safety and tolerability remain separate considerations. Gastrointestinal adverse events, hypoglycemia risk in the context of other medicines, and treatment discontinuation can affect the interpretation of efficacy results.
1. Introduction: Two Outcomes, Two Different Questions
Tirzepatide research often reports two prominent results: lower blood glucose and reduced body weight. Because both may improve during treatment, it can be tempting to combine them into one general statement about effectiveness. Clinical trials, however, need to measure each outcome using methods suited to the question being asked.
Glycemic control is especially important in type 2 diabetes research. Investigators need to know whether a treatment lowers HbA1c, improves fasting glucose, and helps participants reach predefined glycemic targets. They also need to understand the durability of those changes and whether improvements occur without unacceptable safety problems.
Weight management research asks a different set of questions. Investigators may measure mean change in body weight, percentage change from baseline, waist circumference, and the proportion of participants achieving specified weight-loss thresholds.
These outcomes are biologically connected, but they are not interchangeable. Weight reduction can improve glycemia, while tirzepatide also has glucose-regulating effects related to its incretin-receptor activity. A trial that measures both outcomes separately can therefore describe the treatment’s effects more precisely than one that relies on a single summary measure.
For readers in An Giang and elsewhere, this distinction is useful when evaluating clinical-trial summaries, product descriptions, and claims that a single percentage captures every aspect of treatment effectiveness.
2. What Is Tirzepatide?
Tirzepatide is a synthetic peptide-based medicine that activates both the GIP receptor and the GLP-1 receptor. These receptors are involved in incretin signaling, which helps regulate glucose metabolism and influences appetite and food intake.
Its clinical effects can therefore involve multiple pathways. Glucose-dependent insulin secretion and changes in glucagon regulation contribute to its glucose-lowering activity, while effects on appetite and energy intake contribute to weight reduction.
These mechanisms help explain why tirzepatide trials often report improvements in both glycemic and weight outcomes. They do not mean that every participant experiences the same degree of change in each outcome, or that a particular HbA1c result predicts a specific amount of weight loss.
2.1 Why mechanism is not a substitute for measurement
A plausible mechanism can guide researchers in selecting endpoints, but clinical outcomes still need to be measured. Receptor activation does not tell investigators how much HbA1c changed, how many participants achieved a glycemic target, or how many kilograms were lost over the study period.
Those questions require defined measurements, baseline data, a comparison group, and an appropriate statistical analysis.
3. Glycemic Control: What Do Clinical Trials Measure?
Glycemic control refers to the regulation of blood glucose over time. In type 2 diabetes trials, it is commonly assessed using HbA1c, fasting serum glucose, and the proportion of participants reaching specified HbA1c thresholds. Some studies also collect additional glucose measurements or continuous glucose monitoring data.
3.1 HbA1c change from baseline
HbA1c reflects the proportion of hemoglobin that has glucose attached to it. Because red blood cells circulate for a period of months, HbA1c provides an estimate of average glycemia over approximately two to three months.
Clinical trials commonly report the mean change in HbA1c from baseline to a prespecified endpoint, such as week 40. A reduction from 8.2% to 6.2%, for example, represents a decrease of 2.0 percentage points—not a 2% relative reduction.
Trials also compare the treatment group’s change with that of a control or active-comparator group. The difference between groups helps estimate the treatment effect beyond changes that occurred in the comparator group.
3.2 The proportion reaching a glycemic target
A mean HbA1c change does not reveal how many individual participants reached a target. For this reason, tirzepatide trials may report the proportion achieving HbA1c below 7.0%, 6.5% or another prespecified threshold.
These responder outcomes answer a different question from mean change. Two trials could report similar average reductions but different proportions of participants reaching a target if their baseline HbA1c distributions differ.
Target thresholds are also trial endpoints, not universal treatment instructions. In clinical care, appropriate glycemic goals are individualized according to factors such as age, diabetes duration, comorbidities, hypoglycemia risk, and treatment burden.
3.3 Fasting glucose and other glucose measurements
Fasting serum glucose measures blood glucose after a defined fasting period. It can provide information about glycemia that complements HbA1c, but it reflects a different measurement window and can vary from day to day.
Continuous glucose monitoring (CGM), where used, can provide information about time in range, time above range, and time below range. These measures describe glucose patterns that HbA1c alone may not fully capture.
Not every trial uses every measurement. The appropriate interpretation depends on the protocol, the prespecified endpoints, and the population being studied.
4. Body Weight: A Separate Set of Endpoints
Weight-related outcomes are usually measured using a calibrated scale and a prespecified analysis plan. Researchers may report absolute weight change in kilograms, percentage change from baseline, or the proportion of participants reaching a predefined weight-loss threshold.
4.1 Absolute weight change
Absolute weight change is the difference between baseline weight and weight at a specified time point. It is usually reported in kilograms or pounds.
For example, a 10 kg reduction is an absolute change. It is easy to interpret as a quantity, but it does not account for differences in starting body weight between participants.
4.2 Percentage change from baseline
Percentage weight change expresses the difference relative to baseline weight. It allows researchers to compare proportional changes among participants who begin at different weights.
For example, a reduction of 10 kg represents 10% of a 100 kg baseline weight but approximately 12.5% of an 80 kg baseline weight. The same absolute change therefore does not represent the same proportional response for everyone.
4.3 Weight-loss responder thresholds
Trials may report the proportion of participants achieving at least 5%, 10%, 15%, 20%, or another specified amount of weight reduction. These responder analyses help describe the distribution of outcomes rather than only the average response.
In obesity trials, a threshold such as 5% weight reduction can be clinically relevant, but it is still a defined research endpoint. It should not be confused with a guarantee that every participant will reach that threshold or maintain it after treatment ends.
4.4 Waist circumference and body composition
Some studies also assess waist circumference, body composition, or other anthropometric measures. Waist circumference provides information about abdominal size, while body-composition assessments can help estimate fat mass and lean mass.
These measures add context, but they are not equivalent to total body weight. A change in weight alone does not reveal exactly how much fat, lean tissue, or water contributed to the change.
5. Why Glycemic Control and Weight Must Be Analyzed Separately
| Research question | Typical endpoint | What it tells researchers | What it cannot establish alone |
|---|---|---|---|
| Did average glycemia improve? | Change in HbA1c from baseline. | The average change in a longer-term glycemic marker. | How much weight was lost or whether every participant reached a target. |
| Did more participants reach a glycemic target? | Proportion reaching HbA1c below a prespecified threshold. | The distribution of target attainment across participants. | The exact amount of weight change in each participant. |
| How much weight changed? | Mean change in kilograms. | The average absolute weight change. | Whether the change was proportional to baseline weight or whether glycemic goals were met. |
| How large was the proportional response? | Percentage change in body weight. | The change relative to baseline weight. | Whether all lost weight was fat or whether glucose control improved by a specific amount. |
| How many participants reached a weight goal? | Proportion achieving at least 5%, 10%, or another weight reduction. | How commonly a predefined weight response occurred. | Whether participants also reached glycemic targets or maintained the response long term. |
| Was the response tolerable and safe? | Adverse events, hypoglycemia, discontinuation, and other safety outcomes. | The observed safety and tolerability profile during the study. | A complete guarantee of safety for every individual or for unstudied uses. |
Separating these outcomes prevents a common interpretation error: treating a large reduction in one measure as proof that all other measures improved to the same extent.
6. SURPASS-1: Glycemic and Weight Outcomes in the Same Trial
SURPASS-1 was a 40-week, double-blind, randomized, placebo-controlled phase 3 trial involving adults with type 2 diabetes inadequately controlled by diet and exercise alone who had not previously used injectable diabetes therapy.
The primary endpoint was mean change in HbA1c from baseline at week 40. Body weight was evaluated separately among the trial’s efficacy outcomes.
Across the three tirzepatide groups, mean HbA1c decreased by approximately 1.87, 1.89, and 2.07 percentage points for the 5 mg, 10 mg, and 15 mg groups, respectively. The placebo group had a mean HbA1c change of approximately +0.04 percentage points.
Mean body-weight reductions were approximately 7.0 kg, 7.8 kg, and 9.5 kg in the three tirzepatide groups. The results indicate that both glycemic control and body weight improved in the studied population, but each outcome had its own measurement and analysis.
These findings should be interpreted in light of the trial population and duration. They do not establish that every person with type 2 diabetes will experience the same change, nor do they predict the response of people using tirzepatide for a different indication.
7. SURPASS-2: Comparing Tirzepatide With Semaglutide
SURPASS-2 compared three tirzepatide groups with semaglutide 1 mg once weekly in 1,879 adults with type 2 diabetes who were receiving metformin. The trial lasted 40 weeks and was open-label.
The primary objective was to evaluate noninferiority of the higher tirzepatide doses for HbA1c reduction compared with semaglutide. The protocol also specified key secondary objectives related to HbA1c and body weight.
In the published report, tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in this trial. The estimated treatment differences in body weight were approximately −1.9 kg, −3.6 kg, and −5.5 kg for the 5 mg, 10 mg, and 15 mg tirzepatide groups, respectively, compared with semaglutide.
These weight differences are comparisons between randomized treatment groups, not the total weight loss experienced by every participant. The glycemic analysis likewise used a distinct endpoint and comparison framework.
It is also important to recognize the comparator: the trial evaluated semaglutide 1 mg in adults with type 2 diabetes. It should not be interpreted as a direct comparison with every semaglutide formulation, dose, indication, or clinical population.
8. SURMOUNT-1: When Weight Is the Primary Research Question
The SURMOUNT-1 trial illustrates how endpoint selection changes when the research question focuses on obesity rather than treatment of established type 2 diabetes.
This 72-week, double-blind, randomized, placebo-controlled trial enrolled 2,539 adults with obesity or overweight plus at least one weight-related complication, excluding people with diabetes. The coprimary endpoints were percentage change in body weight from baseline and the proportion of participants achieving at least 5% weight reduction.
At week 72, mean body-weight changes were approximately −15.0%, −19.5%, and −20.9% in the tirzepatide 5 mg, 10 mg, and 15 mg groups, compared with −3.1% in the placebo group under the treatment-regimen estimand.
These results answer a weight-management research question in a population without diabetes. They should not be directly compared with HbA1c results from SURPASS trials as if the studies were interchangeable. SURMOUNT-1 did not use HbA1c change as the primary endpoint because it was not designed as a treatment trial in people with established diabetes.
8.1 Why trial populations matter
People with type 2 diabetes and people with obesity without diabetes can differ in baseline glycemia, metabolic characteristics, background medicines, and other clinical factors. Differences in trial duration, endpoints, comparators, and statistical estimands also affect the interpretation of results.
Comparing outcomes across trials can be informative, but it requires attention to these design differences. A percentage weight change in an obesity trial cannot be substituted for an HbA1c change in a diabetes trial.
9. Primary Endpoints, Secondary Endpoints, and Statistical Interpretation
Clinical trials usually prespecify a primary endpoint, which is the principal outcome used to assess the study’s main hypothesis. Secondary endpoints address additional questions and may include other clinically important measures.
In many SURPASS trials, HbA1c change was the primary endpoint, while body weight and the proportion achieving HbA1c targets were among the key secondary endpoints. In SURMOUNT-1, body-weight outcomes were coprimary endpoints.
9.1 Why endpoint hierarchy matters
Primary and key secondary endpoints are typically defined before the trial results are known. This helps limit the risk of selecting only favorable outcomes after examining the data.
When a trial evaluates many endpoints, statistical procedures may be used to control the chance of false-positive findings from multiple comparisons. Exploratory outcomes can still be useful, but they should not automatically be interpreted with the same evidentiary weight as a prespecified primary endpoint.
9.2 Statistical significance is not the same as clinical importance
A statistically significant difference indicates that the observed data are inconsistent with a specified null hypothesis under the analysis assumptions. It does not by itself show how important the difference is to an individual patient.
Clinical interpretation also considers the magnitude of change, uncertainty around the estimate, durability, adverse effects, treatment burden, and relevance to outcomes that matter to patients.
9.3 Estimands and treatment discontinuation
Trials may use different estimands to define the treatment effect they intend to estimate. A treatment-regimen estimand may assess the effect regardless of treatment discontinuation, while an efficacy estimand may address outcomes under a different set of assumptions about adherence and intercurrent events.
These approaches can produce different numerical estimates. When comparing results, readers should check which estimand is being reported rather than assuming that every percentage comes from the same analysis.
If HbA1c is the primary endpoint, the strongest central conclusion concerns glycemic control in the studied population. Weight reduction may be a major secondary finding, but it answers a separate question. When body weight is a coprimary endpoint, as in SURMOUNT-1, the study is designed to evaluate weight outcomes directly. Endpoint hierarchy helps readers distinguish the main evidence from supporting findings.
10. Why Baseline Values Affect the Meaning of Results
The same numerical change can mean different things depending on the starting point. Baseline values are therefore essential for interpreting both glycemic and weight outcomes.
10.1 Baseline HbA1c
A participant starting with a higher HbA1c has more room for a numerical reduction than someone who starts close to a target. Baseline HbA1c distributions can therefore influence mean change and the proportion of participants reaching a target.
This does not mean that a larger numerical reduction always represents a better overall outcome. The result must be interpreted alongside baseline risk, target attainment, hypoglycemia, and other relevant safety measures.
10.2 Baseline body weight
Absolute kilograms lost depend partly on starting weight. Percentage change helps standardize the magnitude of weight change relative to baseline, but it does not eliminate all differences between trial populations.
For example, two participants can lose the same number of kilograms but have different percentage reductions. Conversely, the same percentage reduction can correspond to different absolute weight changes.
10.3 Background medication and diabetes duration
Glycemic outcomes can also depend on background diabetes therapies, diabetes duration, baseline metabolic status, and trial eligibility criteria. Some trials study tirzepatide as monotherapy, while others add it to existing treatments such as metformin or basal insulin.
These settings should not be collapsed into a single universal estimate. The study protocol determines which clinical context the result most directly represents.
11. Safety: Efficacy Outcomes Need a Separate Safety Assessment
Neither HbA1c reduction nor weight loss is a complete measure of a medicine’s overall benefit-risk profile. Clinical trials also collect adverse events, treatment discontinuations, hypoglycemia, and other safety outcomes.
11.1 Gastrointestinal adverse events
Nausea, diarrhea, vomiting, and other gastrointestinal events were among the most common adverse events reported in tirzepatide trials. Many were mild to moderate, but their severity and effect on treatment continuation varied across participants and studies.
These events matter to interpretation because a trial’s efficacy results should be considered alongside tolerability and the proportion of participants who discontinued treatment.
11.2 Hypoglycemia and background treatment
Tirzepatide’s glucose-dependent effects do not eliminate all risk of hypoglycemia. Risk depends in part on concomitant glucose-lowering medicines, especially insulin or insulin secretagogues such as sulfonylureas.
For that reason, hypoglycemia is a distinct safety outcome rather than something that can be inferred from the mean HbA1c reduction. Two treatments with similar HbA1c changes may differ in their hypoglycemia profiles depending on the population and background therapies.
11.3 Other important warnings
Current U.S. prescribing information for tirzepatide-containing products includes important warnings and contraindications, including a boxed warning concerning thyroid C-cell tumors observed in rodents and contraindications related to a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The relevant product label also describes other warnings and precautions.
Product indications differ by brand and jurisdiction. For example, Mounjaro is used for type 2 diabetes in the United States, while Zepbound has U.S. indications for chronic weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Readers should consult the current official label applicable to the product and country rather than assume that every tirzepatide product has identical authorized uses.
A lower HbA1c and a lower body weight can both be meaningful outcomes, but neither establishes that a treatment is safe for every person. Adverse events, hypoglycemia, contraindications, treatment discontinuation, and the duration of follow-up must be evaluated independently. The strongest interpretation considers efficacy and safety together rather than selecting the most impressive numerical result.
12. Statistics and Evidence Snapshot
| Trial or guideline | Population and design | Key result | How to interpret it |
|---|---|---|---|
| SURPASS-1 | 478 adults with type 2 diabetes; 40-week randomized placebo-controlled trial. | Mean HbA1c reductions of about 1.87–2.07 percentage points; mean weight reductions of 7.0–9.5 kg across tirzepatide groups. | Glycemic and weight outcomes were both measured, but each was a distinct endpoint. |
| SURPASS-2 | 1,879 adults with type 2 diabetes; 40-week comparison with semaglutide 1 mg. | Tirzepatide produced greater HbA1c reduction and greater weight reduction than semaglutide 1 mg in the trial. | Results apply to the studied population, doses, comparator, and trial duration. |
| SURMOUNT-1 | 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes; 72 weeks. | Mean weight change was −15.0%, −19.5%, and −20.9% with tirzepatide 5, 10, and 15 mg versus −3.1% with placebo. | A weight-focused obesity trial, not a direct substitute for glycemic endpoints in diabetes trials. |
| ADA Standards of Care in Diabetes—2025 | Clinical practice recommendations for glycemic assessment and goal setting. | HbA1c is a primary tool for glycemic assessment; goals should be individualized. | A trial threshold is not automatically the appropriate target for every individual. |
| FDA Zepbound information | U.S. regulatory information for tirzepatide used in chronic weight management and other authorized indications. | Weight-management efficacy was evaluated in randomized trials over 72 weeks. | Regulatory indications are product- and jurisdiction-specific. |
13. Frequently Asked Questions
Glycemic control describes blood-glucose regulation and is commonly assessed using HbA1c and glucose measurements. Weight loss describes a change in body weight, usually reported in kilograms, percentage of baseline weight, or the proportion reaching a predefined weight-loss threshold.
They are distinct outcomes that answer different questions. HbA1c measures longer-term glycemia, while weight measures a change in body mass. Separate analyses help researchers describe each treatment effect without assuming that one predicts the other.
It means HbA1c fell by two percentage points—for example, from 8.2% to 6.2%. This is not the same as a 2% relative reduction.
No. Weight reduction can contribute to improved glycemia, but the relationship varies. HbA1c and other glucose measures must be evaluated directly to assess glycemic control.
No. HbA1c is a glycemic marker, not a weight measurement. Weight change must be measured and analyzed separately.
The primary endpoint was mean change in HbA1c from baseline at week 40. Body weight was evaluated as a separate outcome.
SURMOUNT-1 focused on weight management in adults with obesity or overweight plus a weight-related complication, excluding diabetes. Its coprimary endpoints were percentage change in body weight and the proportion achieving at least 5% weight reduction. Many SURPASS trials focused primarily on glycemic control in adults with type 2 diabetes.
Kilograms lost is an absolute change. Percentage weight loss expresses that change relative to baseline weight. The same number of kilograms can represent different percentages for people with different starting weights.
It means the study’s principal efficacy question is centered on the prespecified HbA1c outcome. Secondary endpoints, including weight change, can still be important, but they answer additional questions.
Not necessarily. Statistical significance should be considered alongside the size of the effect, uncertainty, durability, safety, and relevance to outcomes that matter to patients.
HbA1c reduction and weight loss do not reveal the full safety profile. Trials also evaluate adverse events, hypoglycemia, discontinuation, and other outcomes that help characterize the treatment’s benefit-risk profile.
No. Trial averages describe groups, not guaranteed individual outcomes. Baseline characteristics, other medicines, adherence, tolerability, and clinical context can affect individual responses.
14. Related Articles and Educational Resources
- Knowledge Hub — explore research-oriented articles on peptide science, metabolic health, and clinical evidence.
- Peptide FAQ — review common questions about peptide products, evidence quality, and research limitations.
- Peptide Products and Research Information — explore product listings while distinguishing commercial descriptions from independently established clinical evidence.
15. Related Research Products
Tirzepatide 20mg — Research Product Listing
This listing relates to the compound discussed in this article. A commercial product listing does not establish that the product is equivalent to an approved prescription medicine, has been evaluated in the cited clinical trials, or is suitable for human use. Product identity, formulation, quality, sterility, and regulatory status are separate questions.
Retatrutide 20mg — Related Investigational Peptide Listing
Retatrutide is a distinct investigational triple-hormone receptor agonist studied for metabolic outcomes. Findings from tirzepatide trials should not be transferred to retatrutide, because the molecules, trial programs, evidence bases, and regulatory status differ. A product listing is not proof of clinical approval or equivalence.
Related Educational Resource: Fat Loss Peptide Plan
The Fat Loss Peptide Plan is a related educational resource for readers exploring weight-management research. It should not be interpreted as a validated treatment protocol or a recommendation to use research-only products. Clinical decisions involving diabetes or weight-management medicines require appropriate professional assessment.
16. Scientific References
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503–515. DOI: 10.1056/NEJMoa2107519. PubMed.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398:143–155. PubMed.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. DOI: 10.1056/NEJMoa2206038. PubMed.
- Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021. PubMed.
- Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Effect of Tirzepatide versus Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Clinical trial evidence and endpoint details. PubMed record.
- American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Supplement 1):S128–S145. DOI: 10.2337/dc25-S006.
- American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Supplement 1):S167–S180. Journal article.
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. Information on tirzepatide (Zepbound), its U.S. weight-management indication, and the randomized trials supporting approval. FDA announcement.
- U.S. National Library of Medicine. DailyMed: Zepbound (tirzepatide) Prescribing Information. Current U.S. product labeling, indications, warnings, and clinical study information. DailyMed label.
Conclusion: Glycemic Control and Body Weight Are Related, but They Are Not the Same Outcome
Tirzepatide clinical trials evaluate glycemic control and body weight separately because each measurement answers a different question. HbA1c, fasting glucose, and glycemic-target attainment describe aspects of glucose regulation. Kilograms lost, percentage weight change, and weight-loss responder thresholds describe changes in body weight.
The SURPASS program illustrates how both types of outcome can be assessed in adults with type 2 diabetes, often with HbA1c as the primary endpoint and body weight as a key secondary endpoint. SURMOUNT-1 illustrates a different design in which body-weight outcomes were coprimary endpoints in adults with obesity or overweight without diabetes.
These differences in population, endpoint hierarchy, comparator, and duration matter when comparing trial results. A large HbA1c reduction does not reveal the exact amount of weight lost, and a substantial weight reduction does not by itself establish that glycemic goals were achieved safely.
Safety, tolerability, treatment discontinuation, and the regulatory indication must also be considered. Trial averages describe the participants studied; they do not guarantee an individual outcome or establish that every product marketed under a compound name matches the medicine used in clinical trials.
The central conclusion: The most accurate interpretation of tirzepatide research keeps glycemic control, body weight, and safety as distinct but complementary dimensions of evidence. Understanding how each endpoint is measured is essential to evaluating what a clinical trial actually demonstrates—and what it does not.